168 related articles for article (PubMed ID: 1790404)
1. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses.
Reeve J; Bradbeer JN; Arlot M; Davies UM; Green JR; Hampton L; Edouard C; Hesp R; Hulme P; Ashby JP
Osteoporos Int; 1991 Jun; 1(3):162-70. PubMed ID: 1790404
[TBL] [Abstract][Full Text] [Related]
2. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone.
Bradbeer JN; Arlot ME; Meunier PJ; Reeve J
Clin Endocrinol (Oxf); 1992 Sep; 37(3):282-9. PubMed ID: 1424211
[TBL] [Abstract][Full Text] [Related]
3. Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur.
Reeve J; Mitchell A; Tellez M; Hulme P; Green JR; Wardley-Smith B; Mitchell R
J Bone Miner Metab; 2001; 19(2):102-14. PubMed ID: 11281158
[TBL] [Abstract][Full Text] [Related]
4. Human parathyroid peptide treatment of vertebral osteoporosis.
Reeve J; Arlot ME; Bradbeer JN; Hesp R; Mcally E; Meunier PJ; Zanelli JM
Osteoporos Int; 1993; 3 Suppl 1():199-203. PubMed ID: 8461559
[TBL] [Abstract][Full Text] [Related]
5. Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis.
Reeve J; Arlot M; Price TR; Edouard C; Hesp R; Hulme P; Ashby JP; Zanelli JM; Green JR; Tellez M
Eur J Clin Invest; 1987 Oct; 17(5):421-8. PubMed ID: 3121346
[TBL] [Abstract][Full Text] [Related]
6. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.
Hodsman AB; Fraher LJ
Bone Miner; 1990 May; 9(2):137-52. PubMed ID: 2161692
[TBL] [Abstract][Full Text] [Related]
7. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride.
Reeve J; Davies UM; Hesp R; McNally E; Katz D
BMJ; 1990 Aug; 301(6747):314-8. PubMed ID: 2393738
[TBL] [Abstract][Full Text] [Related]
8. Calcium-47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis: the influence of human parathyroid fragment (hPTH 1-34) therapy.
Reeve J; Arlot M; Bernat M; Charhon S; Edouard C; Slovik D; Vismans FJ; Meunier PJ
Metab Bone Dis Relat Res; 1981; 3(1):23-30. PubMed ID: 7266363
[No Abstract] [Full Text] [Related]
9. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium.
Lindsay R; Zhou H; Cosman F; Nieves J; Dempster DW; Hodsman AB
J Bone Miner Res; 2007 Apr; 22(4):495-502. PubMed ID: 17227219
[TBL] [Abstract][Full Text] [Related]
10. A small dose of human parathyroid hormone(1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis.
Sone T; Fukunaga M; Ono S; Nishiyama T
Miner Electrolyte Metab; 1995; 21(1-3):232-5. PubMed ID: 7565456
[TBL] [Abstract][Full Text] [Related]
11. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).
Buxton EC; Yao W; Lane NE
J Clin Endocrinol Metab; 2004 Jul; 89(7):3332-6. PubMed ID: 15240611
[TBL] [Abstract][Full Text] [Related]
12. Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.
Gafni RI; Brahim JS; Andreopoulou P; Bhattacharyya N; Kelly MH; Brillante BA; Reynolds JC; Zhou H; Dempster DW; Collins MT
J Bone Miner Res; 2012 Aug; 27(8):1811-20. PubMed ID: 22492501
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
15. Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone.
Boyce RW; Paddock CL; Franks AF; Jankowsky ML; Eriksen EF
J Bone Miner Res; 1996 May; 11(5):600-13. PubMed ID: 9157775
[TBL] [Abstract][Full Text] [Related]
16. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide.
Lindsay R; Cosman F; Zhou H; Bostrom MP; Shen VW; Cruz JD; Nieves JW; Dempster DW
J Bone Miner Res; 2006 Mar; 21(3):366-73. PubMed ID: 16491283
[TBL] [Abstract][Full Text] [Related]
17. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients.
Hodsman AB; Steer BM; Fraher LJ; Drost DJ
Bone Miner; 1991 Jul; 14(1):67-83. PubMed ID: 1868270
[TBL] [Abstract][Full Text] [Related]
18. Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment.
Miki T; Nakatsuka K; Naka H; Masaki H; Imanishi Y; Ito M; Inaba M; Morii H; Nishizawa Y
J Bone Miner Metab; 2004; 22(6):569-76. PubMed ID: 15490267
[TBL] [Abstract][Full Text] [Related]
19. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
[TBL] [Abstract][Full Text] [Related]
20. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
